In this trial (NCT04348045), patients with disease control following 4 months of FOLFIRINOX receive maintenance olaparib if they have a BRCA1/2 mutation or other evidence of “BRCAness” in their somatic tumor profile; the remaining subjects who do not fit this criteria but whose tumors harbor a KRAS mutation are randomized to receive either durvalumab (an anti-PD-L1 monoclonal antibody) plus the MEK inhibitor selumetinib or continued chemotherapy with FOLFIRI. The gene discussed is KRAS; the disease is neoplasm.